Literature DB >> 21042023

Obesity affects the liver - the link between adipocytes and hepatocytes.

Alexander Wree1, Alisan Kahraman, Guido Gerken, Ali Canbay.   

Abstract

The incidence of obesity has dramatically increased in recent years. Consequently, obesity and associated disorders such as nonalcoholic fatty liver disease (NAFLD) constitute a serious threat. Therefore, the contribution of visceral adipose tissue to metabolic homeostasis has become a focus of interest. Visceral adipose tissue secretes free fatty acids (FFAs) and hormones, known as adipokines, and thus seems to play a major role in the development of NAFLD. Apoptotic cell death is a prominent feature in nonalcoholic steatohepatitis (NASH). Indeed, toxic FFAs can activate the intrinsic apoptosis pathway in hepatocytes via c-Jun N-terminal kinase (JNK). JNK activates the proapoptotic protein Bim, resulting in Bax activation and enhanced apoptosis, termed 'lipoapoptosis'. Reduced adiponectin levels may establish a proinflammatory milieu, thus increasing vulnerability to lipotoxicity, which promotes progression from simple steatosis to NASH and even advanced hepatic fibrosis. Moreover, obesity seems to be a risk factor for hepatocellular carcinoma, the most frequent liver cancer subtype. Even in acute liver failure, a high body mass index is associated with poor outcome, and recent data suggest a major role of obesity in the progression of chronic hepatitis C and B. This review summarizes current knowledge - highlighting the inflammatory and cytokine view - of the intimate relationship between adipose and liver tissue.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 21042023     DOI: 10.1159/000318741

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  67 in total

1.  Adipokine expression in brown and white adipocytes in response to hypoxia.

Authors:  A Wree; A Mayer; S Westphal; A Beilfuss; A Canbay; R R Schick; G Gerken; P Vaupel
Journal:  J Endocrinol Invest       Date:  2011-09-27       Impact factor: 4.256

Review 2.  The role of Klotho in energy metabolism.

Authors:  M Shawkat Razzaque
Journal:  Nat Rev Endocrinol       Date:  2012-05-29       Impact factor: 43.330

Review 3.  Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.

Authors:  Alexander Wree; Wajahat Z Mehal; Ariel E Feldstein
Journal:  Semin Liver Dis       Date:  2016-02-12       Impact factor: 6.115

4.  Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation.

Authors:  A Wree; C D Johnson; J Font-Burgada; A Eguchi; D Povero; M Karin; A E Feldstein
Journal:  Cell Death Differ       Date:  2015-04-24       Impact factor: 15.828

5.  Diet containing low n-6/n-3 polyunsaturated fatty acids ratio, provided by canola oil, alters body composition and bone quality in young rats.

Authors:  Carlos Alberto Soares da Costa; Aluana Santana Carlos; Gabrielle de Paula Lopes Gonzalez; Rejane Pontes Gaspar Reis; Mariana Dos Santos Ribeiro; Aline de Sousa Dos Santos; Alexandra Maria Vieira Monteiro; Egberto Gaspar de Moura; Celly Cristina Alves do Nascimento-Saba
Journal:  Eur J Nutr       Date:  2011-05-26       Impact factor: 5.614

Review 6.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

7.  Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis.

Authors:  Azza S M Awad; Ekram N Abd Al Haleem; Wesam M El-Bakly; Mohie A Sherief
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-01-12       Impact factor: 3.000

8.  Regional variations in the relationship between arterial stiffness and adipocyte volume or number in obese subjects.

Authors:  P Arner; J Bäckdahl; P Hemmingsson; P Stenvinkel; D Eriksson-Hogling; E Näslund; A Thorell; D P Andersson; K Caidahl; M Rydén
Journal:  Int J Obes (Lond)       Date:  2014-07-08       Impact factor: 5.095

9.  Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers.

Authors:  Margreke J E Brill; Anne van Rongen; Aletta P I Houwink; Jacobus Burggraaf; Bert van Ramshorst; René J Wiezer; Eric P A van Dongen; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447

10.  Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults.

Authors:  Yvonne N Flores; Rafael Velázquez-Cruz; Paula Ramírez; Manuel Bañuelos; Zuo-Feng Zhang; Hal F Yee; Shen-Chih Chang; Samuel Canizales-Quinteros; Manuel Quiterio; Guillermo Cabrera-Alvarez; Nelly Patiño; Jorge Salmerón
Journal:  Mol Biol Rep       Date:  2016-10-17       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.